December 25, 2014 1:48 AM ET

Pharmaceuticals

Company Overview of Zyngenia, Inc.

Executive Profile

Peter A. Kiener D.Phil.

Chief Scientific Officer, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 5 Board Members in 5 different organizations across 11 different industries.

See Board Relationships
62--

Background

Dr. Peter A. Kiener, D.Phil. has been Chief Scientific Officer at Sucampo Pharmaceuticals, Inc. since October 2014. Dr. Kiener was a Co-Founder of Zyngenia, Inc. Dr. Kiener served as Chief Executive Officer and President of Zyngenia, Inc. and leads business and drug development efforts. Dr. Kiener served as Chief Scientific Officer of Ambrx, Inc. since August 2013. Dr. Kiener served as a Board Observer of Virdante Pharmaceuticals, Inc. He served as an Executive Vice ...

Corporate Headquarters

21 Firstfield Road
Gaithersburg, Maryland 20878

United States

Phone: 410-467-1176
Fax: --

Board Members Memberships

Former Director
Former Board Observer
Former Chief Executive Officer, President and Director
Chairman

Education

PhD
University of Oxford
BS
Lancaster University

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

There is no Total Compensation data available.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
$621.0K
A. J. Kazimi MBAFounder, Chairman, Chief Executive Officer and President
Cumberland Pharmaceuticals, Inc.
$620.0K
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
--
Jeffrey M. Yordon Founder, Chairman and Chief Executive Officer
Sagent Pharmaceuticals, Inc.
$615.2K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zyngenia, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.